The Efficacy of Oral Probiotics on Neonatal Hyperbilirubinemia
NCT ID: NCT03876678
Last Updated: 2023-07-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
180 participants
INTERVENTIONAL
2019-05-24
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Probiotics on Neonatal Hyperbilirubinemia
NCT02807246
COMPARISON OF ZINC AND PROBIOTICS ON NEONATES WITH INDIRECT HYPERBILIRUBINEMIA UNDERGOING PHOTOTHERAPY
NCT07102836
Safety Evaluation of Lactobacillus Salivarius AP-32 and Bifidobacterium Animalis Subsp. Lactis CP-9 in Healthy Infants.
NCT04140604
Gut Microbiome Associated Study of Shanghai Infants With Jaundice
NCT03510936
Origin of the Neonatal Gut Microbiota and Probiotic Intervention
NCT06241222
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
At present, it has been confirmed that Escherichia coli (E. coli) in the intestine of animals produces two harmful bacterial enzymes, β-glucosidase and β-glucuronidase. Therefore, in recent years, scientists have used probiotics that inhibit the growth characteristics of pathogenic bacteria to study the treatment of neonatal jaundice. Chen Yi-Ji et al. have shown that probiotics inhibit the activity of intestinal β-glucuronidase, preventing the conversion of conjugated bilirubin to unconjugated bilirubin, thereby reducing the level of unconjugated bilirubin in the blood. Funda Tuzun et al.'s research indicates that bifidobacteria probiotics prevent breast milk jaundice, and probiotics prevent jaundice by increasing intestinal peristalsis and microbial flora. In addition, many studies have shown that Lactobacillus and Bifidobacterium species have inhibitory efficacy on intestinal β-glucuronidase activity, but there is no specific indication of which strain has the best inhibitory efficacy. Based on the above research, the question investigators need to clarify is whether oral probiotics can correct the intestinal microbial flora of newborns of jaundice? Is there any difference in the improvement of neonatal jaundice by the addition of probiotics in breast milk, formula or mixed milk? Therefore, this study will first screen out the probiotics that have the best inhibitory efficacy of intestinal β-glucuronidase activity. In the second stage, the results of the first stage will be used to perform a neonatal jaundice oral probiotic double-blind randomized trial and the therapeutic efficacy will be observed.
This trial will be carried out in two stages in the sick baby room of the Children's Hospital of China Medical University (CMUH). The first stage is: the API ZYM kit was used to determine the β-glucuronidase activity of 9 strains of Lactobacillus and 4 strains of Bifidobacterium, screening out the probiotics that have the best inhibitory efficacy of intestinal β-glucuronidase activity; The second stage is: using the results of the first stage analysis, treating the newborns of jaundice by oral probiotics. The inclusion criteria of jaundice infants were as follows: the full-term infant (≧37 weeks) had a jaundice index greater than 15 mg/dl on the fourth day after birth, while neonates with hypothyroidism, trisomy 21, maternal blood type A, B and O incompatibility, gastrointestinal disease, Glucose-6-Phosphate Dehydrogenase deficiency (G6PD deficiency), hemangioma, cephalhaematoma or hemorrhages, severe asphyxia (stage III), fetal chromosomal anomalies, cyanotic congenital heart disease, omphalocele, early onset sepsis or liver failure were excluded. The second stage of jaundice newborns will be divided into three groups: (I. experimental group) light therapy + Lactobacillus salivarius AP-32 (L. salivarius AP-32), (II. experimental group) light therapy + Bifidobacterium animalis subspecies lactis CP-9 (B. animalis subsp. lactis CP-9), (III. control group) light therapy + placebo. The study will be conducted for 7 days, the serum bilirubin level will be measured by the same group of experienced nurses every day, and all babies are monitored for adverse conditions such as vomiting, diarrhea or bloating.
Calculation of sample size in the second stage: According to Chou Hung-Chieh et al.'s research, the incidence of neonatal hyperbilirubinemia was 30.5% for a concentration ≧15 mg/dl. investigators assume that the experimental group has a 50% improvement compared with the control group. If investigators allow 5% chance of type 1 error (α=0.05) and 10% chance of type 2 error(β=0.1), then the required sample size in each group will be 60 people (total 180 babies).
The research data will be based on statistical software (called IBM SPSS) for analytical statistics. Normally distributed data were analyzed using Student's t-test two-tailed assay, and non-normally distributed data were analyzed using the Wilcoxon signed-rank test. Data were presented as mean ± standard deviation (SEM) or median, with P values \< 0.05 being considered statistically significant.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Light therapy and oral L. salivarius AP-32
Light therapy and taking 1 L. salivarius AP-32 probiotic capsule two times everyday for 7 days.
Lactobacillus salivarius AP-32
Taking 1 probiotic capsule two times everyday for 7 days.
Light therapy and oral B. animalis subsp. lactis CP-9
Light therapy and taking 1 B. animalis subsp. lactis CP-9 probiotic capsule two times everyday for 7 days.
Bifidobacterium animalis subspecies lactis CP-9
Taking 1 probiotic capsule two times everyday for 7 days.
Light therapy and oral placebo
Light therapy and taking 1 placebo capsule two times everyday for 7 days.
Placebo
Taking 1 placebo capsule two times everyday for 7 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lactobacillus salivarius AP-32
Taking 1 probiotic capsule two times everyday for 7 days.
Bifidobacterium animalis subspecies lactis CP-9
Taking 1 probiotic capsule two times everyday for 7 days.
Placebo
Taking 1 placebo capsule two times everyday for 7 days.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Jaundice index greater than 15 mg/dl on the fourth day after birth.
Exclusion Criteria
2. Trisomy 21
3. Maternal blood type A, B and O incompatibility
4. Gastrointestinal disease
5. Glucose-6-Phosphate Dehydrogenase deficiency (G6PD deficiency)
6. Hemangioma
7. Cephalhaematoma or hemorrhages
8. Severe asphyxia (stage III)
9. Fetal chromosomal anomalies
10. Cyanotic congenital heart disease
11. Omphalocele
12. Early onset sepsis
13. Liver failure
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
China Medical University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ming-Luen Tsai
Attending physician
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hung-chih Lin
Role: STUDY_DIRECTOR
China Medical University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
China Medical University Hospital
Taichung, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CMUH107-REC1-136
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.